Welcome to our dedicated page for Gain Therapeutics news (Ticker: GANX), a resource for investors and traders seeking the latest updates and insights on Gain Therapeutics stock.
Gain Therapeutics, Inc. (Nasdaq: GANX) is a clinical-stage biotechnology company whose news flow is closely tied to the development of its lead drug candidate, GT-02287, and to progress in its broader allosteric small molecule pipeline. The company focuses on next generation allosteric therapies targeting neurodegenerative diseases, rare genetic disorders and oncology, with a primary emphasis on Parkinson’s disease.
News about Gain Therapeutics frequently covers clinical milestones for GT-02287, including updates from its Phase 1 and Phase 1b studies in people with Parkinson’s disease with or without a GBA1 mutation. Press releases have detailed safety and tolerability findings, exploratory biomarker data such as reductions in glucosylsphingosine (GluSph) in cerebrospinal fluid, and observations related to Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) scores. These items provide insight into how the company interprets GT-02287’s potential disease-modifying effects and mechanism of action.
Investors and observers can also expect regular announcements on preclinical research and scientific presentations. Gain Therapeutics reports data from preclinical models that explore GCase modulation, mitochondrial and lysosomal health, and neuroprotection in Parkinson’s disease. Poster presentations at scientific meetings, such as Neuroscience conferences and Parkinson’s-focused congresses, are common subjects of the company’s news releases.
Additional news items include corporate updates and financial disclosures, such as quarterly financial results, capital raises, changes in board composition, and shareholder meeting outcomes. The company also issues notices about participation in investor conferences, key opinion leader (KOL) events, and webinars that discuss biomarkers, clinical endpoints and emerging data from GT-02287 studies.
For readers following GANX, the news page provides a centralized view of clinical trial progress, scientific data, regulatory and corporate developments, and event participation related to Gain Therapeutics’ efforts in allosteric small molecule drug development.
Gain Therapeutics, Inc. (Nasdaq: GANX) will participate in the Cantor Virtual Global Healthcare Conference from September 27th-30th, showcasing its innovative approach to targeting allosteric binding sites for neurodegenerative diseases. CEO Eric Richman will present on September 30, from 8:00 to 8:30 a.m. ET, with a webcast available for interested investors. Gain Therapeutics aims to redefine drug discovery using its SEE-Tx™ platform, unlocking new treatment options for challenging disorders.
Gain Therapeutics (Nasdaq: GANX) announced that CEO Eric Richman will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit from September 20-23, 2021. The presentation is scheduled for September 22 from 1:15 to 1:55 p.m. ET. Investors can participate via webcast and one-on-one meetings. Gain Therapeutics focuses on optimizing allosteric binding sites in treatments for neurodegenerative diseases.
Gain Therapeutics, focused on neurodegenerative diseases, announced a presentation by Dr. Manolo Bellotto on their allosteric regulators for GM1 Gangliosidosis and Morquio B Disease. The presentation will take place on September 14, 2021, at 2:00 PM PT/5:00 PM ET during the GM1 Virtual Community Conference. These diseases are linked to mutations in the GLB1 gene, leading to toxic substrate accumulation. Gain's STARs aim to potentially treat neurological symptoms, marking a significant advancement in the field.
Gain Therapeutics (Nasdaq: GANX) reported positive topline data from its study on two STAR compounds, GT-02287 and GT-02329, aimed at treating Gaucher Disease and GBA1 Parkinson’s Disease. Conducted at the University of Maryland, the study showed increased GCase protein levels, enhanced enzymatic activity, and decreased α-synuclein in neurons. The company plans to present comprehensive data at an upcoming Michael J. Fox Foundation webinar and initiate IND-enabling studies in Q4 2021, further supporting its Site-Directed Enzyme Enhancement Therapy (SEE-Tx™) platform.
Gain Therapeutics (GANX) announced positive topline data from a study on its compounds GT-02287 and GT-02329 for treating Gaucher and GBA1 Parkinson's Disease. The study showed increased GCase protein levels and activity, along with a decrease in toxic α-synuclein levels. Conducted in collaboration with the University of Maryland School of Medicine, findings will be presented in a webinar organized by the Michael J. Fox Foundation. The company plans to initiate IND-enabling studies for these treatments in Q4 2021.
Gain Therapeutics (Nasdaq: GANX), a biotechnology company specializing in neurodegenerative and lysosomal storage disorders, announced that CEO Eric Richman will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. An on-demand presentation will be available starting September 13, 7:00 am ET for 90 days. Richman and CFO Salvatore Calabrese are available for virtual 1x1 meetings during the conference. Gain is focused on innovative drug discovery and is supported by organizations like The Michael J. Fox Foundation.
Gain Therapeutics, Inc. (GANX) reported a cash position of $43.16 million as of June 30, 2021, significantly up from $7.49 million at the end of 2020. The company continues to advance its developmental programs while expanding its intellectual property portfolio, including two new patents targeting misfolded proteins linked to neurodegenerative diseases. Revenues for Q2 2021 reached $89,000, up from $7,000 in Q2 2020, primarily due to collaboration with Zentalis Pharmaceuticals. However, net losses increased to $3.56 million compared to $543,000 a year earlier.
Gain Therapeutics (Nasdaq: GANX) announced that CEO Eric Richman will present a corporate overview at the BTIG Virtual Biotechnology Conference on August 9-10, 2021. His presentation is scheduled for 11:30 to 11:55 a.m. ET on August 9. Gain Therapeutics specializes in drug discovery targeting protein misfolding associated with neurodegenerative diseases and lysosomal storage disorders. The event expects participation from over 120 management teams and offers thematic panels and one-on-one meetings.
Gain Therapeutics (Nasdaq: GANX) announced the issuance of two PCT patents on June 10, 2021, targeting compounds for misfolded enzymes associated with neurodegenerative and lysosomal storage diseases. The patents include PCT/IB2020/061158, which addresses diseases like Gaucher Disease and Parkinson’s Disease, and PCT/IB2020/061156, focused on conditions linked to GALC alterations. CEO Eric Richman emphasized this as a significant milestone for developing new therapies for these challenging diseases, reinforcing the company's intellectual property and commitment to innovation.
Gain Therapeutics, Inc. (Nasdaq: GANX), a biotechnology firm, will present a corporate overview at the Jefferies Virtual Healthcare Conference from June 1 to June 4, 2021. CEO Eric Richman is set to speak on June 1 at 3:00 PM ET. The session will be accessible via webcast and will be available for replay on the company's website for 30 days post-conference. This annual conference gathers over 400 healthcare companies and 3,000 investors to discuss investment opportunities and trends in healthcare.